|This message contains images. If you don't see images, click here to view.|
Advertise in this news brief.
Cost-effectiveness of new direct-acting antivirals to prevent post-liver transplant recurrent hepatitis
American Journal of Transplantation (login required)
Preliminary studies on HCV-cirrhotics listed for transplant suggest that sofosbuvir in combination with ribavirin is very effective in promoting viral clearance and preventing disease recurrence. Unfortunately, the high cost of such treatment (€46 500 per 12 weeks of treatment) makes its cost-effectiveness questionable. A semi-Markov model was developed to assess the cost-effectiveness of sofosbuvir/ribavirin treatment in cirrhotic patients without HCC (HCV-CIRRH) and with HCC (HCV-HCC) listed for transplant. In the base-case analysis, the incremental cost-effectiveness ratio for 24 weeks of sofosbuvir/ribavirin was €44 875 per quality-adjusted life-year gained in HCV-CIRRH and €60 380 in HCV-HCC patients.
Registration open for ASTS Leadership Development Program
This year's program will be held Sept. 27-30 at Northwestern University’s Kellogg School of Management. Transplant clinicians and their administrative counterparts are encouraged to attend this highly customized, one-of-a-kind course together.
Smile to support transplantation research
The Foundation of the American Society of Transplant Surgeons has partnered with Amazon Smile. Just start your shopping here and the ASTS Foundation will automatically receive 0.5 percent of the price of your eligible Amazon Smile purchases.
Registration open for OPTN/UNOS Liver Forum
The OPTN/UNOS Liver and Intestinal Organ Transplantation Committee is sponsoring an educational forum to seek additional input on concepts intended to increase equity in access to liver transplantation. The forum will be held June 22, 2015, at the Loews Chicago O'Hare Hotel and will also be available for live webinar participation.
Livers donated after cardiac death safe for use by liver cancer patients
Oncology Nurse Advisor
Liver cancer patients have the same beneficial outcomes using organs donated by patients who died of cardiac death as using organs from those who died from brain death. The study was recently published in the American Journal of Transplantation. Patients with liver cancer can be cured with a liver transplant. But because of the shortage of donated organs, these patients often die waiting for a liver. That's because most transplant centers predominantly use livers from donors who die from brain death.
You care about your transplant
patients. And so do we. That’s
why we’re introducing Astellas
Cares—a new program that
offers you customized tools,
educational resources, and
comprehensive support to help
your patients care for their
health. To register, visit
Energy expenditure, spontaneous physical activity and with weight gain in kidney transplant recipients
Clinical Nutrition (login required)
Nineteen transplanted non-diabetic men, 53 ± 1.6 years old, receiving calcineurin inhibitors but no corticosteroids were studied. They were compared with nine healthy men matched for height, age and lean body mass. Daily energy expenditure and its components (sleeping, basal and absorptive metabolic rates) were analyzed for 24 h in calorimetric chambers and for 4 days in free living conditions using calibrated accelerometry. Other variables known to influence energy expenditure were assessed: body composition, physical activity, 4-day food intake, drug consumption, serum C-reactive protein, interleukin-6, thyroid and parathyroid hormones, and epinephrine.
The effect of state policies on organ donation and transplantation in the United States
Shortages in transplantable solid organs remain a critical public health challenge in the United States. During the past 2 decades, all states have implemented policies to increase organ supply, although their effectiveness is unknown. The aim of this study was to determine the effects on organ donation and transplantation rates of state policies to provide incentives for volunteer donation.
Missed an issue of ASTS NewsBrief? Click here to visit the ASTS NewsBrief archive page.
Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody
American Journal of Transplantation (login required)
Understanding rates and determinants of clinical pathologic progression for recipients with de novo donor-specific antibody (dnDSA), especially subclinical dnDSA, may identify surrogate endpoints and inform clinical trial design. A consecutive cohort of 508 renal transplant recipients was studied. Recipients without dnDSA or dysfunction had an eGFR decline of -0.65 mL/min/1.73 m2/year. In recipients with dnDSA, the rate eGFR decline was significantly increased prior to dnDSA onset and accelerated post-dnDSA, suggesting that dnDSA is both a marker and contributor to ongoing alloimmunity.
Bacteria linked to hyperammonemia in lung transplant patients
By Chelsea Adams
New research shows a rare but often fatal complication among lung transplant patients is likely caused by bacteria normally found in the urinary tract. Dr. Ankit Bharat, a thoracic surgeon and surgical director at the Northwestern University Feinberg School of Medicine in Chicago, found elevated levels of ammonia in a 44-year-old double lung transplant patient a week after transplant surgery. Reasons for the patient's hyperammonemia weren't clear.
Early occurrence of new-onset diabetes after transplantation is related to type of liver graft and warm ischaemic injury
Liver International (login required)
Researchers studied new-onset diabetes after transplantation in liver transplantation with grafts donated after brain death or circulatory death (DCD), focusing on the early post-transplant period.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063